Resources

Meeting the Ever-changing Needs of Pediatric MTP
Presented at the SABM Annual Meeting 2021

Introducing a new cryoprecipitated coagulopathy treatment: INTERCEPT® Fibrinogen Complex
Presented at the SABM Annual Meeting 2021

Watch or Learn More

INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex:

CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.

Cerus.com

INTERCEPT-USA.com

HCP.INTERCEPT-USA.com

INTERCEPT-Canada.com

INTERCEPTBloodSystem.com

INTERCEPT-Cryoprecipitation.com

Resources

INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex:

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS